（文章来源：证券日报） 证券日报网讯富士莱11月25日在互动平台回答投资者提问时表示，公司与恒瑞医药的合作进展顺利，公 司期待以此为基础，未来拓展更多合作机会。 ...

Core Viewpoint - Fujifilm announced on November 25 that it has received the GMP compliance inspection result notification from the Jiangsu Provincial Drug Administration, confirming that its active pharmaceutical ingredient, Apatinib Mesylate, meets GMP standards, laying a solid foundation for future commercialization [1] Group 1 - The company has successfully passed the GMP compliance inspection for its raw material drug Apatinib Mesylate [1] - This compliance is crucial for the subsequent commercialization of the product [1]

Core Viewpoint - Fujilai plans to deepen its existing business layout in the coming year, actively seizing market opportunities through product structure optimization, cost reduction, efficiency enhancement, and steady market expansion to achieve sustainable development and stable performance improvement [1] Group 1 - The company aims to optimize its product structure [1] - The company is focused on cost reduction and efficiency enhancement [1] - The company intends to steadily expand its market presence [1]

Core Viewpoint - Fujifilm announced on November 25 that it is a major manufacturer of alpha-lipoic acid series products, alongside Tonghe Pharmaceutical, and expects a 5.47% year-on-year increase in the shipment volume of its core product, granular alpha-lipoic acid, in the first half of 2025 due to proactive market expansion strategies and flexible pricing policies [1]. Company Summary - Fujifilm is actively expanding its market presence and implementing flexible pricing strategies to enhance its product competitiveness [1]. - The company anticipates a growth in shipment volume of granular alpha-lipoic acid, indicating a positive outlook for its core product line [1]. Industry Summary - The alpha-lipoic acid market is characterized by significant competition, with Fujifilm and Tonghe Pharmaceutical being key players in the export segment [1]. - The expected growth in shipment volume reflects a broader trend of increasing demand for alpha-lipoic acid products in the market [1].

Core Points - Fujilai announced the completion of its share repurchase program as of November 20, 2025, having repurchased a total of 1,090,000 shares [1] - The repurchased shares represent 1.1890% of the company's total share capital [1]

Core Viewpoint - Fujilai (301258.SZ) has successfully completed a share repurchase program, acquiring 1,090,000 shares, which represents 1.1890% of the company's total share capital, in compliance with its established plan and relevant regulations [1] Summary by Categories Share Repurchase Details - The repurchase was conducted through the Shenzhen Stock Exchange's centralized bidding system [1] - The highest transaction price was 35.80 CNY per share, while the lowest was 33.88 CNY per share [1] - The total amount spent on the repurchase was 37,944,238.00 CNY, excluding transaction fees [1] Compliance and Financial Implications - The total funds used for the repurchase exceeded the lower limit set in the repurchase plan but did not surpass the upper limit [1] - The repurchase program has been fully implemented in accordance with the company's established plan and relevant legal requirements [1]

Group 1 - The company Fujilai (SZ 301258) announced a share buyback of 1.09 million shares, representing 1.189% of its total share capital, with a total transaction amount of approximately 37.94 million yuan [1] - The buyback was executed at a maximum price of 35.8 yuan per share and a minimum price of 33.88 yuan per share, and the total funds used for the buyback exceeded the lower limit of the buyback plan but did not exceed the upper limit [1] - As of the report date, Fujilai's market capitalization is 3.1 billion yuan [1] Group 2 - For the year 2024, Fujilai's revenue composition is heavily weighted towards pharmaceuticals, accounting for 99.19% of total revenue, while other businesses contribute only 0.81% [1]

证券代码：301258 证券简称：富士莱 公告编号：2025-066 苏州富士莱医药股份有限公司 关于回购股份实施完成暨股份变动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）于 2025 年 10 月 13 日召 开第五届董事会第二次会议，审议通过了《关于使用自有资金回购公司股份方案 的议案》，同意公司使用自有资金通过集中竞价交易方式回购公司人民币普通股 （A 股），并在未来适宜时机用于股权激励计划或员工持股计划。本次回购股份 资金总额不低于人民币 2,000 万元（含本数）且不超过人民币 4,000 万元（含本 数），回购价格不超过人民币 40.00 元/股（含）。回购期限自公司董事会审议通 过本次回购股份方案之日起不超过 12 个月。具体内容详见公司于 2025 年 10 月 14 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于使用自有资金回购公 司股份方案的公告》（公告编号：2025-053）。 截至 2025 年 11 月 20 日，公司本次回购股份事项已实施完毕，根据《深圳 证 ...

Group 1 - The company Fuji Lai (301258) responded to investor inquiries on November 12, indicating that as of November 10, 2025, the total number of shareholders is 10,653 [1]

Core Viewpoint - Recent market rumors suggest that the silicon material and component alliance has been rejected by the National Development and Reform Commission and the regulatory authority, leading to significant declines in the photovoltaic and energy storage sectors [1] Industry Summary - The China Photovoltaic Industry Association expresses confidence in the industry's ability to succeed with central government support and coordination among enterprises, while dismissing circulating rumors as false information [1] - The association emphasizes its commitment to protecting national and industry interests and plans to combat malicious actions aimed at undermining the photovoltaic sector [1] Company Summary - The "Storage and Acquisition Plan Alliance" involves leading companies in the polysilicon sector aiming to consolidate the industry by acquiring and shutting down approximately 1 million tons of production capacity, ultimately controlling capacity between 2.2 to 2.5 million tons to ensure a 60-70% operational rate [1]